This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the strengthening of its global commercial. (2021-01-11 | TSX:TH) Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units. stock news by MarketWatch. Stockhouse. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors Stockhouse. Cookies are used to offer you a better browsing experience and to analyze our traffic. By continuing to use our service, you agree to our use of cookies. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Competitors: Unknown. Theratechnologies affirms fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the range of 13% and 20% as. By continuing to use our service, you agree to our use of cookies. Their average twelve-month price target is $36. Theratechnologies Unveils New Positive Data for Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers. Cookies are used to offer you a better browsing experience and to. com. com. Further. 9%, while the Biotechs industry saw earnings growing at 17. THERATECHNOLOGIES INC. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. These companies provide a lot of detail to the OTC Markets Group including audited financials. We also use them to share usage information with our partners. (TSX: EXRO) (OTCQB: EXROF) (the "Company" or "Exro" ), a leading clean technology company which has developed a new class of power electronics for electric motors and powertrains, announced today its financial results for the three months ended March 31, 2022. 02%. Microsoft (NDAQ:MSFT) will expand its presence in Quebec with new computing capacity and AI and. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter and first half of. MONTREAL, Nov. Stockhouse. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its first quarter 2023 ended February 28, on Wednesday, April. 00, suggesting a possible upside of. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has established an at-the-market ("ATM") equity program allowing Theratechnologies to. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced dosing of the first participant in Part 3 of its Phase 1 clinical trial of. By continuing to use our service, you agree to our use of cookies. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter and first half of. THERATECHNOLOGIES INC. About TH1902. com. FDA for its IV push form of administration of Trogarzo. This news release constitutes a “designated news release” for the purposes of the Company’s. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. com. Stockhouse. Overview Stock Screener Earnings Calendar Sectors Nasdaq | THTX U. . Theratechnologies Inc. The firm offers its product under the brand name of EGRIFTA, which is an approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. $103. Stockhouse. It's a different kind of fat that may require a different type of treatment. By continuing to use our. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. It’s lead investigational peptide drug conjugate linked to docetaxel, a well-established and well-characterized cytotoxic agent used in the. (NASDAQ:NASDAQ:THTX) Q1 2022 Earnings Conference Call April 13, 2022 8:30 AM ETCompany ParticipantsPaul Levesque - President & CEOPhilippe Dubuc - SVP &. Theratechnologies layoffs. (NASDAQ:NASDAQ:THTX) Q3 2022 Earnings Conference Call October 13, 2022 8:30 AM ETCompany ParticipantsElif McDonald - Head of Investor RelationsPaul Levesque -. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨Theratechnologies has established its SORT1+ Technology™ platform as an engine for the development of proprietary peptide-drug conjugates (PDCs) that target the sortilin (SORT1) receptor, which is expressed in multiple tumor types. By continuing to use our service, you agree to our use of cookies. Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 ir@theratech. Theratechnologies Draws Down on US$20 Million Second Tranche Under its Term Loan Facility With Affiliates of Marathon Asset Management. Gary Littlejohn. Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and. 22, 2023 (GLOBE NEWSWIRE) -- B2Gold Corp. 04, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. 9 million, adjusted EBITDA of $2. The company’s marketed products include Egrifta SV is indicated to reduce excess abdominal fat in human immunodeficiency virus (HIV. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. Apr 14, 2020, 8:30 a. Theratechnologies' CFO to Attend Piper Jaffray 31st Annual Healthcare Conference in New York City. MONTREAL, April 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. The company’s previously announced offering was conducted by a syndicate of underwriters, including companies such as Canaccord Genuity. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] Inc. (2022-02-10 | TSX:TH) Theratechnologies to Announce Financial Results for Its Fourth Quarter and Full Fiscal Year 2021. Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. Cookies are used to offer you a better browsing experience and to. By continuing to use our service, you agree to our use of cookies. Northwest also announces an update on its. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second quarter. (2020-10-22 | TSX:TH) Theratechnologies to Present at Upcoming Investor Conferences on October 29 and November 10, 2020. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Common Shares (THTX) Stock Price, Quote, News & History | Nasdaq Nasdaq Data Link's products page Investors may trade in the Pre-Market (4:00. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ¨ Form 40-F xToronto, Ontario-- (Newsfile Corp. Cookies are used to offer you a better browsing experience and to analyze our traffic. Biopharmaceutical company Theratechnologies (TH) has closed its bought deal public offering after raising over C$58 million in proceeds. Gary Littlejohn Stockhouse. com uses cookies on this site. . - TH1902 Phase 1 basket trial proceeding as planned. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Stockhouse. home message. The Notes were issued under a trust indenture dated as of June 19, 2018, by and among Theratechnologies and Computershare Trust Company of Canada. (TSX: TH) announced today that the Supreme Court of Canada has granted its appeal and dismissed 121851 Canada Inc. : Renegotiated Lease to Generate Substantial Annual Savings Stockhouse. This news release constitutes a “designated news release” for the purposes of the. Join the discussion: Find out what everybody’s saying about this stock on the Theratechnologies Bullboard, and check out the rest of Stockhouse’s stock forums and message boards. TO) stock quote, history, news and other vital information to help you with your stock trading and investing. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company will present data from tissue microarrays showing high expression of. D. TH | May 19, 2023. Once expert advice is considered, the Company. TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (Sort1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Sep 13. com uses cookies on this site. TH | February 28, 2023. Forecast to breakeven in 2024 Jul 15. 4. We also use them to share usage. We also use them to share usage information with our partners. Theratechnologies, Inc. Learn why it. Investor inquiries: Elif McDonald. Cookies are used to offer you a better browsing experience and to analyze our traffic. (2015-07-23 | TSX:TH) Theratechnologies Announces $9,600,000 Firm Offering of Units and Filing of Preliminary Short Form Prospectus. (TH. 06 million, an increase of 14. View analysts price targets for THTX. 66% compared to the previous year's 69. 57%) Q1 2020 Earnings Call. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies,. (“Teuton” or “the Company”) (TSXV:TUO) (Frankfurt:TFE) has received news from its joint venture partner, Tudor Gold Corp. Data presented at AMCP Nexus 2023. Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of a notification letter (the “Notification Letter. Theratechnologies Inc. Marsolais’ presentation will be available through. - Cash, bonds and money market funds of US$22. 1M. Revenues have been growing at an average rate of 10. T. 1-514-336-7800. 82 million. T. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has decided to pause the enrollment of patients in its Phase 1 clinical. Stockhouse. Theratechnologies's earnings have been declining at an average annual rate of -35. 33. 4%. Agreement in principle on key amendments to loan. 40% on the last trading day (Friday, 17th Nov 2023), rising from $1. com uses cookies on this site. Stockhouse. Denis Boucher. Remember, high Theratechnologies' alpha is almost always a sign of. Volatility Over Time: TH's weekly volatility has increased from 16% to 25% over the past year. 51 S1. [email protected] Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update T. Theratechnologies Appoints New Board Member. Senior Director, Investor Relations. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 1-438. . Theratechnologies will acquire all outstanding shares of Katana for US$5,300,000 or CA$6,900,000. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. MONTREAL, Feb. Theratechnologies Announces 1-for-4 Reverse Stock Split. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) today announced the publication of a preclinical study demonstrating the in vitro and in vivo efficacy of TH1902, an investigational sortilin (SORT1)-targeted peptide-drug conjugate, in inhibiting ovarian cancer and triple-negative breast cancer (TNBC. It’s lead investigational peptide drug conjugate linked to docetaxel, a well-established and well-characterized cytotoxic agent used in the treatment of. The ADRIQ (Association pour le développement de la recherche et de l’innovation du Québec) rewards Quebec-based companies for leadership and innovation in their respective. Theratechnologies (TSX:TH)has indicated that Trogarzo did not meet its primary endpoints in its IM method study. By continuing to use our service, you agree to our use of cookies. MONTREAL, Oct. Headquartered in Montreal, Quebec (Canada), Theratechnologies commercializes two medicines in HIV and has research programs in HIV, NASH and Oncology. (2022-04-27 | TSX:TH) Theratechnologies to Focus Its Commercialization Activities on the North American Territory. However, it did not meet the equivalence limits of 0. Stockhouse. Theratechnologies Inc. Theratechnologies to Announce Financial Results for Its First Quarter 2022. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. acts as investment manager. Betteryear2. is a pharmaceutical company. 9 million as at August 31, 2023. (“Theratechnologies”) with the Securities and Exchange Commission (the. ET. Stockhouse. 5% workforce reduction. Montréal, Québec, Canada . 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691. View recently published Stock News reports from independent reports and journalists. FY2023 revenue guidance range set between $90 million and $95 million. Theratechnologies reduces R&D head count to compensate for sales setback. MONTREAL, April 03, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 9 million and US. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. MONTREAL, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Investor inquiries: Elif McDonald. 26, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Theratechnologies Inc. When this page refreshes you will be logged in with the new address. 5000 0. Cookies are used to offer you a better browsing experience and to analyze our traffic. (2022-09-12 | TSX:TH) Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth. was a. 2 million. 46. com uses cookies on this site. About SORT1+ Technology™ and TH1902. 124. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (TSX: TH, Forum) has long been a favourite among Healthcare Bullboard posters who have been following its developments to commercialize innovative therapies. 74M. MONTREAL, May 25, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. has received a $100 million binding commitment with respect to a non-dilutive term loan with an affiliate of Marathon Asset Management. Jours fériés des marchés. Theratechnologies Inc (Theratechnologies) is a biopharmaceutical company that focuses on the discovery and development of drugs for people with orphan medical conditions. The abstract and poster can be found on Theratechnologies’ website. Phone Number 15143319691. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Story. (THTX) NasdaqCM - NasdaqCM Real Time Price. We currently market prescription products for people with. 22, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Gain a better understanding of ETFs with our ETF Insights and ETF 101 resource. stock news by MarketWatch. TO) Stock Price, News, Quote & History - Yahoo Finance Canada Markets close in 43 mins S&P/TSX 20,125. Stockhouse. P. (“Theratechnologies” or the “Company”) (TSX: TH) today announced that it has applied to list its common shares on NASDAQ. com. 36 morning pop. $44. Stockhouse. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its fourth quarter and full year fiscal 2022 ended November 30,. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. By continuing to use our service, you agree to our use of cookies. 5%. By continuing to use our service, you agree to our use of cookies. BioSyent is continuously looking to source pharmaceutical products that have been successfully developed and proven to be safe and effective. The Montreal-based biopharmaceutical company's consolidated net revenues for fourth quarter 2020 are expected to be between US$18. 29(+0. com. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 ir@theratech. By continuing to use our service, you agree to our use of cookies. We also use them to share usage information with our partners. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. com uses cookies on this site. stockhouse. Theratechnologies Announces Fiscal Year 2023 Guidance and Operating Plan’s Key Objectives. com. 4%. (TSX-V: TLT, Forum) has demonstrated proof-of-concept for its Canadian-made COVID-19 vaccine. We also use them to share. By continuing to use our service, you agree to our use of cookies. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies stated the primary endpoint measured a 90 per cent confidence interval of the IM injection to IV injection (0. m. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. com. The company develops treatments for lipodystrophy . (NASDAQ:THTX) Q2 2022 Earnings Conference Call July 14, 2021 8:30 AM ET. When this page refreshes you will be logged in with the new address. Cookies are used to offer you a better browsing experience and to analyze our traffic. Montréal, Québec, Canada . By continuing to use our service, you agree to our use of cookies. Stockhouse. 03) EPS for the quarter, beating the consensus estimate of ($0. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has decided to pause the enrollment of patients in its Phase 1 clinical trial of. MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Watch list NEW Set a price target alert After Hours Last. com uses cookies on this site. If you have HIV, it's important to know the difference. lgibson. Theratechnologies Inc. Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Microsoft to invest $500M in Quebec AI economy. Amendment Withdraws the Condition to File HFS Report to the FDA to Access the US$20 Million Second Tranche. Cookies are used to offer you a better browsing experience and to analyze our. MONTREAL, July 14, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. TH | October 13, 2022 - Q3 2022 Consolidated. 25, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, Nov. We also use them to share usage. By continuing to use our service, you agree to our use of cookies. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. 86 million for the quarter. MONTREAL, Oct. Theratechnologies inc. com uses cookies on this site. Join the discussion: Find out what everybody’s saying about this stock on the Theratechnologies Bullboard, and check out the rest of Stockhouse’s stock forums and message boards. Read More. Register for your free account today at data. Cookies are used to offer you a better browsing experience and to analyze our traffic. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. About Us | Theratechnologies Inc. Q4 2022 consolidated revenue growth of 14. For investor inquiries: Leah Gibson. Get the latest Theratechnologies Inc (THTX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Senior Director, Communications & Corporate Affairs. TH | September 26, 2023. 65 per cent to C$1. MONTREAL, Oct. (2022-07-27 | TSX:TH) Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement Stockhouse. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. The company reported ($0. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. The company's proprietary technologies include Long Acting Peptides, a peptide stabilization technology that. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented preclinical data that demonstrate the potential utility of its lead investigational. Who is Theratechnologies. This peptide-drug conjugate (PDC) is the lead candidate stemming from Theratechnologies’ SORT1+ Technology™ in oncology. com uses cookies on this site. Theratechnologies inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has established an at-the-market ("ATM") equity program allowing Theratechnologies to issue and sell up to US $50 million common shares from. (2019-08-12 | TSX:TH) Theratechnologies Files Application to List on NASDAQ. MONTREAL, Feb. 81 million for the quarter. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies was founded in 1993 and currently employs more than 150 people in Canada, the United States and Europe. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a commercial-stage biopharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical. About Theratechnologies. MONTREAL, Feb. We also use them to share usage information with our partners. 28, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. TH 48% v4,15M c1. . (“Theratechnologies” or the “Company”) (TSX: TH) today announced that it has applied to list its common shares on NASDAQ. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650WELCOME TO SEDAR+ File, disclose and search for issuer information in Canada’s capital markets Search SEDAR+ All public disclosure documents Reporting Issuers List Filing organizations from all jurisdictions Disciplined List People and companies under disciplinary action Cease Trade Orders People and companies restricted from trading securities Sign. com uses cookies on this site. com. For investor inquiries: Leah Gibson. : Renegotiated Lease to Generate Substantial Annual Savings. 69, 1. C. Metastasis is a form of cancer that has spread from its original site to a distant site or organ where it grows or metastasizes. WELCOME TO SEDAR+ File, disclose and search for issuer information in Canada’s capital markets Search SEDAR+ All public disclosure documents Reporting Issuers List Filing organizations from all jurisdictions Disciplined List People and companies under disciplinary action Cease Trade Orders People and companies restricted from trading securities Sign. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it plans to pursue Phase 3 clinical development of tesamorelin for the treatment of Non-Alcoholic Steatohepatitis (NASH) in. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and. com uses cookies on this site. US Headquarters. 22M. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 [email protected] uses cookies on this site. 4% from the stock's current price. Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc. Stockhouse. By continuing to use our service, you agree to our use of cookies. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus. During the last trading day the stock fluctuated 12. Theratechnologies Inc. 01, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. We also use them to share usage information with our partners. By continuing to use our service, you agree to our use of cookies. (2020-11-03 | TSX:TH) Theratechnologies Announces Departure of Chief Commercial Officer. MONTREAL, Jan. Track Theratechnologies Inc. Further. communications@theratech. Heures de négociation. Fri, 17 Apr 2015 15:08:33 GMT ~ Supreme Court of Canada rules in favour of Theratechnologies. Following the release, Knight will hold a conference call and audio webcast. com uses cookies on this site. The abstracts are now available at aacr.